TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Outcomes of concomitant bedaquiline and delamanid in patients with multidrug-resistant TB

Concomitant treatment with bedaquiline and delamanid (Bdq-Dlm) was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) infection, according to results of a study published in Clinical Infectious Diseases.

Read the full story at Infectious Disease Advisor.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Shannon Storms

Published: March 23, 2022, 2:37 p.m.

Last updated: Nov. 14, 2024, 7:29 p.m.

Print Share